106 completed, 22 terminated, 10 recruiting, 9 unknown. 160 Phase 2, 43 Phase 1, 2 Phase 3.
Follow Oligodendroglioma: new trials by email Literature Review of Oligodendroglioma trials Research Report on Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) SRN-101 - Recurrent High Grade Gliomas, Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | Siren Biotechnology | 40 | 2026-12-01 | 2026-10-28 |
| Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® GammaTile® - Glioma, Glioblastoma | Phase 2 | Not yet recruiting | University of California, Irvine | 20 | 2026-10-01 | 2026-09-23 |
| Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. Pre-radiation temozolomide. - High Grade Gliomas, Glioblastoma | Phase 2 | Recruiting | The Cooper Health System | 70 | 2026-07-13 | 2026-10-09 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 [C-11]-CS1P1, Brain MRI - Central Nervous System Cancer, Brain Metastases | Phase 2 | Recruiting | Washington University School of Medicine | 104 | 2026-04-16 | 2026-04-21 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Study of Olutasidenib and Temozolomide in HGG Olutasidenib + TMZ - High Grade Glioma, Astrocytoma | Phase 2 | Recruiting | Rigel Pharmaceuticals | 60 | 2025-02-01 | 2026-09-01 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma Tislelizumab plus Bevacizumab - Oligodendroglioma | Phase 2 | Recruiting | Henan Provincial People's Hospital | 80 | 2022-12-23 | 2022-09-27 |
| Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq - Recurrent High-grade Glioma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Dawonmedax Co., Ltd. | 7 | 2022-12-05 | 2025-02-21 |
| All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Retifanlimab, All-trans retinoic acid - Glioma, IDH Mutation | Phase 2 | Recruiting | Stephen Bagley, MD, MSCE | 55 | 2022-11-16 | 2026-02-20 |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants OKN-007 - Glioblastoma, Astrocytoma | Phase 1 / Phase 2 | Withdrawn | Oblato, Inc. | 2022-08-01 | 2022-10-07 | |
| PARP Inhibition for Gliomas (PI-4G or π4g) Niraparib - Recurrent Glioblastoma, Recurrent Astrocytoma | Phase 2 | Terminated | University of Oklahoma | 15 | 2022-06-09 | 2025-05-23 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations Pemigatinib - Glioblastoma, Adult-type Diffuse Gliomas | Phase 2 | Terminated | Incyte Corporation | 83 | 2022-05-20 | 2025-12-30 |
| SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Mirdametinib - Low-Grade Glioma, Recurrent Low-Grade Glioma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 132 | 2021-06-21 | 2026-09-11 |
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma | Phase 2 / Phase 3 | Withdrawn | NRG Oncology | 2020-01-31 | 2026-05-07 | |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy - Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-01-30 | 2026-07-16 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab - Giant Cell Glioblastoma, Gliosarcoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2019-12-01 | 2020-07-24 |
Showing 20 of 160. Sign in to see all of them.
Astrocytoma (143) · Glioblastoma (102) · Glioma (94) · Brain Neoplasms (90) · Central Nervous System Neoplasms (75) · Gliosarcoma (71) · Ependymoma (25) · Medulloblastoma (18) · Glioma, Subependymal (14) · Optic Nerve Glioma (14) · Familial ependymoma (13) · Meningioma (12) · Choroid Plexus Neoplasms (9) · Neuroblastoma (8)
Neoplasms by Histologic Type (160) · Neoplasms, Glandular and Epithelial (160) · Neoplasms, Nerve Tissue (160) · Neuroectodermal Tumors (160) · Neoplasms (159) · Neoplasms, Germ Cell and Embryonal (159) · Neoplasms, Neuroepithelial (158) · Neoplasms by Site (122) · Nervous System Diseases (122) · Nervous System Neoplasms (121) · Central Nervous System Diseases (105) · Brain Diseases (103) · Glioma (66) · Central Nervous System Neoplasms (44) · Cranial Nerve Diseases (16)
Temozolomide (34) · Bevacizumab (16) · Radiotherapy (15) · Carboplatin (10) · Irinotecan (8) · Carmustine (7) · Magnetic Resonance Spectroscopy (6) · Erlotinib Hydrochloride (5) · Filgrastim (5) · Cisplatin (4) · Cyclophosphamide (4) · Etoposide (4) · Peripheral Blood Stem Cell Transplantation (4) · Procarbazine (4) · Surgical Procedures, Operative (4)
National Cancer Institute (NCI) (20) · Duke University (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · New Approaches to Brain Tumor Therapy Consortium (6) · Memorial Sloan Kettering Cancer Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Jonsson Comprehensive Cancer Center (4) · Radiation Therapy Oncology Group (4) · University of California, San Francisco (4) · Alliance for Clinical Trials in Oncology (3) · Herbert Irving Comprehensive Cancer Center (3) · M.D. Anderson Cancer Center (3) · Northwestern University (3) · St. Jude Children's Research Hospital (3) · Wake Forest University Health Sciences (3)
United States (133) · Canada (15) · Netherlands (9) · United Kingdom (9) · France (8) · Switzerland (8) · Germany (6) · Italy (6) · Australia (5) · Belgium (5) · Denmark (4) · Austria (3) · New Zealand (3) · Puerto Rico (3) · Spain (3)
Henry S. Friedman, MD (6) · Edward G. Shaw, MD (5) · Susan M. Chang, MD (4) · Darell D. Bigner, MD, PhD (3) · Edward Pan, MD (3) · Howard A. Fine, MD (3) · James J. Vredenburgh, MD (3) · Jeffrey Raizer, MD (3) · Maryam Fouladi (3) · Patrick Wen, MD (3) · Antonio Omuro, MD (2) · Charles S. Hesdorffer, MD (2) · Evanthia Galanis, MD (2) · Glenn J. Lesser, MD (2)
PMID 11772431, PMID 12649108, PMID 12829671, PMID 14586216, PMID 14670747, PMID 14769140, PMID 15292713, PMID 15514370, PMID 15565574, PMID 16012795, PMID 16133802, PMID 16200343, PMID 16533878, PMID 16549835, PMID 16817692, PMID 16863926, PMID 16914578, PMID 17317837, PMID 17470857, PMID 17610262, PMID 18094423, PMID 18182667, PMID 18779504, PMID 18824712, PMID 18850068, PMID 18976072, PMID 18981004, PMID 18989154, PMID 19066728, PMID 20143438, PMID 20308655, PMID 20381270, PMID 20716591, PMID 20878446, PMID 21242491, PMID 21377994, PMID 21547395, PMID 21632852, PMID 22323663, PMID 22851558, PMID 23243055, PMID 23388559, PMID 24419119, PMID 24470557, PMID 24670608, PMID 25098701, PMID 25338318, PMID 26860632, PMID 27050206, PMID 27109549
U01CA062399 (6), U10CA098543 (4), U01CA081457 (3), U10CA180868 (3), P30CA008748 (2), P30CA033572 (2), U10CA025224 (2), U10CA081851 (2), 2009 (1), 2015 (1), N01CM62202 (1), N01CM62203 (1), N01CM62206 (1), N01CM62207 (1), P30CA006516 (1)